1. Search Result
Search Result
Results for "

dopamine (DA)

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

2

Peptides

2

Natural
Products

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0979

    α-Lobeline hydrochloride; L-Lobeline hydrochloride

    nAChR Dopamine Transporter Neurological Disease
    Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation .
    Lobeline hydrochloride
  • HY-160440A

    mAChR Neurological Disease
    VU6021625 is a selective antagonist muscarinic acetylcholine receptors (mAChRs), with the IC50 value of 0.44 nM, 57 nM for human M4 and rat M4, respectively .
    VU6021625
  • HY-B1423

    α-Lobeline; L-Lobeline

    Lobeline (α-Lobeline) is a brain-penetrant nicotinic receptor agonist. Lobeline increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline is effective in smoking cessation .
    Lobeline
  • HY-118461

    Dopamine Receptor Neurological Disease
    PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .
    PD 120697
  • HY-128420

    α-Lobeline sulfate; L-Lobeline sulfate

    nAChR Dopamine Transporter Neurological Disease
    Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation .
    Lobeline sulfate
  • HY-16736A

    EB-1020 hydrochloride

    Adrenergic Receptor Dopamine Transporter Serotonin Transporter Neurological Disease Endocrinology
    Centanafadine (hydrochloride) is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.
    Centanafadine hydrochloride
  • HY-16736

    EB-1020

    Adrenergic Receptor Dopamine Transporter Serotonin Transporter Neurological Disease Endocrinology
    Centanafadine is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively.
    Centanafadine
  • HY-121650A

    Dopamine Receptor Neurological Disease
    ADTN hydrobromide is a long-acting dopamine agonist. ADTN hydrobromide significantly decreases the behavioral visual threshold of DA-IPC-depleted zebrafish .
    ADTN hydrobromide
  • HY-145454A

    (-)-3-PPP

    Dopamine Receptor Neurological Disease
    Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. Preclamol inhibits the locomotor activity of mice and rats in low doses .
    Preclamol
  • HY-145454

    (+)-3-PPP

    Dopamine Receptor Neurological Disease
    (R)-Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. (R)-Preclamol inhibits the locomotor activity of mice and rats in low doses .
    (R)-Preclamol
  • HY-121685A

    Potassium Channel Neurological Disease
    Tipepidine hydrochloride reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine hydrochloride subsequently activates VTA dopamine neuron . Tipepidine hydrochloride, a non-narcotic antitussive, exerts an antidepressant-like effect .
    Tipepidine hydrochloride
  • HY-121685

    Potassium Channel Neurological Disease
    Tipepidine reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine subsequently activates VTA dopamine neuron . Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect .
    Tipepidine
  • HY-123837

    Dopamine Receptor Neurological Disease
    MLS1082 is a pyrimidone-based D1-like dopamine receptor positive allosteric modulator, with an EC50 of 123 nM for DA-stimulated G protein signaling .
    MLS1082
  • HY-122495

    rel-LY 141865 dihydrochloride

    Dopamine Receptor Neurological Disease
    rel-Quinpirole (rel-LY 141865) dihydrochloride, an ergot compound, is a selective dopamine (DA) D2 receptor agonist. rel-Quinpirole dihydrochloride can be used for research on neurological diseases .
    rel-Quinpirole dihydrochloride
  • HY-W014728

    Dopamine Receptor Cardiovascular Disease Neurological Disease
    N-Methyldopamine hydrochloride is a precursor of adrenaline in the adrenal medulla. N-Methyldopamine hydrochloride is a modification of the dopamine (DA), and retains agonist activity at the DA1 receptor. N-Methyldopamine hydrochloride remains capable of universal surface coating and secondary reactions using the surface catechols. N-Methyldopamine hydrochloride can be used for heart failure research .
    N-Methyldopamine hydrochloride
  • HY-108448

    OLDA

    TRP Channel Cardiovascular Disease
    N-Oleoyldopamine (OLDA) is a product of condensation of oleic acid and dopamine (DA) and an endogenous TRPV1 selective agonist. N-Oleoyldopamine (OLDA) can crosses the blood-brain barrier. N-oleoyl-dopamine protects the heart against ischemia-reperfusion injury via activation of TRPV1 .
    N-Oleoyldopamine
  • HY-10684

    ACR16; ASP2314; FR310826

    Dopamine Receptor Neurological Disease
    Pridopidine, a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S1R) with Ki between 70 and 80 nM, which is ~100× higher than its affinity toward D2R.
    Pridopidine
  • HY-103147

    CU32-085 hydrochloride

    5-HT Receptor Dopamine Receptor Neurological Disease
    Mesulergine (CU32-085) hydrochloride is a potent 5-HT2C antagonist and dopamine (DA) agonist. Mesulergine hydrochloride presentes hyperphagia. Mesulergine hydrochloride has the potential for the research of cognitive processes .
    Mesulergine hydrochloride
  • HY-138806

    Others Neurological Disease
    PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells .
    PAQ
  • HY-P3294

    BIM-23A760; TBR-760

    Dopamine Receptor Somatostatin Receptor Neurological Disease Cancer
    Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .
    Onzigolide
  • HY-W152604

    Cyclo(leu-gly)

    Dopamine Receptor Neurological Disease
    Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .
    Cyclo(glycyl-L-leucyl)
  • HY-N2003

    D-Tetrahydropalmatine is an isoquinoline alkaloid, mainly in the genus Corydalis . D-Tetrahydropalmatine is a dopamine (DA) receptor antagonist with preferential affinity toward the D1 receptors . D-Tetrahydropalmatine is a potent organic cation transporter 1 (OCT1) inhibitor .
    D-Tetrahydropalmatine
  • HY-107674

    nAChR Neurological Disease
    bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC50=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .
    bPiDDB
  • HY-148867

    2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl

    Dopamine Receptor Neurological Disease
    UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .
    UCM-1306
  • HY-152170

    nAChR Neurological Disease
    bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .
    bPiDI
  • HY-109112

    RP5063

    Dopamine Receptor 5-HT Receptor Neurological Disease Inflammation/Immunology
    Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (Ki=1.5 nM) and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .
    Brilaroxazine
  • HY-17385
    Atomoxetine hydrochloride
    3 Publications Verification

    Tomoxetine hydrochloride; (R)-Tomoxetine hydrochloride; LY 139603

    Adrenergic Receptor Serotonin Transporter Sodium Channel Neurological Disease Cancer
    Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with Ki values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na + channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .
    Atomoxetine hydrochloride
  • HY-128121

    Dopamine Receptor Neurological Disease
    MLS1547 is a highly efficacious G protein-biased dopamine D2 receptor (D2R) agonist (Ki=1.2 μM). MLS1547 stimulates D2R G protein-mediated signaling (EC50=0.37 μM in a calcium mobilization assay). MLS1547 acts as an antagonist for dopamine (DA)-stimulated β-arrestin recruitment to the D2R (IC50=9.9 μM) .
    MLS1547
  • HY-W061043

    Serotonin Transporter Dopamine Transporter Neurological Disease
    DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
    DOV-216,303
  • HY-14472

    NS-2330

    Dopamine Transporter Serotonin Transporter Metabolic Disease
    Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
    Tesofensine
  • HY-107370

    Tomoxetine; (R)-Tomoxetine

    Serotonin Transporter Sodium Channel Neurological Disease
    Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na + channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research .
    Atomoxetine
  • HY-124619

    FKBP HIV Infection Neurological Disease
    GPI-1046 is a immunophilin ligand without antibiotic action and attenuates ethanol intake in part through the upregulation of glutamate transporter 1 (GLT1) in PFC and NAc-core. GPI-1046 is an analog of FK506, which is an immunophilin ligand that has been shown neuroprotective effects in neurodegenerative disease models . GPI-1046 readily crosses the blood-brain barrier and promotes the regeneration of dopamine (DA) cells in the CNS in association with functional recovery in rodent models . GPI-1046 improves HIV-associated injury of peripheral nerves .
    GPI-1046

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: